Law360, New York (August 09, 2012, 3:06 PM ET) -- A Pennsylvania federal judge on Tuesday set a deadline date for heart disease claims against GlaxoSmithKline PLC over diabetes drug Avandia, which could retroactively reduce the number of claims in a broader multidistrict litigation against the pharmaceutical giant.
The ruling will affect only claims that use of the drug led to heart disease. In dismissing claims by Marvin Rainey and Amjad Faheem that the drug caused their heart attacks, U.S. District Judge Cynthia Rufe said a series of events in 2007 publicizing the connection between Avandia...
Judge Potentially Limits Claims in Avandia MDL
To view the full article, take a free trial now.
